TABUTEAU HERRIOT sold $10.5M of AXSM
TABUTEAU HERRIOT (Chief Executive Officer) sold 49,664 shares of Axsome Therapeutics, Inc. (AXSM) at an average of $212.19 ($212.01–$213.95, $10.54M total) across 2 trades over 2026-08-05 to 2026-08-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The key actionable element is the disclosed magnitude ($10.54M) and that it was executed under a pre-arranged 10b5-1 plan, which generally lowers informational content versus discretionary selling.
Market read
Traders may briefly reassess sentiment around AXSM due to insider selling, but the 10b5-1 framing suggests limited fundamental signal.
What to watch
The filing does not disclose reasons for the sale beyond the plan; traders should avoid extrapolating fundamentals from a single planned transaction without corroborating news.
Background
This is an SEC Form 4 insider transaction disclosure for Axsome Therapeutics, Inc. (AXSM).
Ticker impact
Axsome CEO TABUTEAU HERRIOT sold 49,664 shares in open-market trades for about $10.54M under a pre-arranged 10b5-1 plan.
Likely limited, short-lived impact unless paired with other company-specific catalysts.
The filing is a primary Form 4 disclosure with transaction size and pricing, yet it explicitly states a pre-arranged 10b5-1 plan, which typically dampens inference about new negative information.
Market effects
No direct sector read-through; this is company-specific insider activity in a biotech/therapeutics name.
None indicated beyond potential micro-level sentiment for AXSM.
None indicated.
Counterpoint
The sale may be routine liquidity management under a 10b5-1 plan, so it may not reflect any change in Axsome’s outlook.
Key entities
- issuerAxsome Therapeutics, Inc.
Subject of the Form 4 insider sale by its CEO.
- insiderTABUTEAU HERRIOT
CEO, officer/director/10% owner who sold shares.
